Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | JAGX | Common Stock | Options Exercise | +12.1K | 12.1K | May 18, 2022 | Direct | F1, F2 | |||
holding | JAGX | Common Stock | 4.43K | May 18, 2022 | See Footnote | F2, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | JAGX | Restricted stock units | Options Exercise | $0 | -12.1K | -100% | $0.00* | 0 | May 18, 2022 | Common Stock | 12.1K | Direct | F1, F2, F4 |
Id | Content |
---|---|
F1 | Restricted stock units convert into common stock on a one-for-one basis. |
F2 | On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. |
F3 | Securities held directly by JBS Healthcare Ventures LLC. Mr. Siegel, by virtue of his position as the sole member of JBS Healthcare Ventures LLC, may be deemed to beneficially own the securities held by JBS Healthcare Ventures LLC for purposes of Section 16. |
F4 | The restricted stock units were previously reported as covering 36,400 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on May 18, 2021 and vested in full on May 18, 2022, the first anniversary of the grant date. |